In particular, in first-line or second-line treatment strategies, the development of specific antibodies targeting programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) has resulted in unprecedented prolongation of survival time for some lung adenocarcinoma patients [4]. Here, CD274 is linked to lung adenocarcinoma.